Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Gastroenterology

• Publication date

  2010-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.gastro.2009.11.014PMID 19931262
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Faculty Opinions recommendation of Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.

  2010cited by this paper
• 414 Proton Pump Inhibitors, H2 Antagonists, and Risk of Hip Fracture: A Large Population-Based Study

  2009cited by this paper
• A reference standard for the description of osteoporosis.

  2008cited by this paper
• Validation of ten-year fracture risk prediction: a clinical cohort study from the Manitoba Bone Density Program.

  2008cited by this paper
• Proton pump-inhibiting drugs, calcium homeostasis, and bone health.

  2008cited by this paper
• The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.

  2008cited by this paper
• Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors

  2008cited by this paper
• Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults

  2008cited by this paper
• Technology Insight: noninvasive assessment of bone strength in osteoporosis

  2008cited by this paper
• Advanced CT bone imaging in osteoporosis

  2008cited by this paper
• Use of proton pump inhibitors and risk of osteoporosis-related fractures

  2008cited by this paper
• Function, structure and regulation of the vacuolar (H+)-ATPases.

  2008cited by this paper
• Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men.

  2007cited by this paper
• Clinical risk factors for fracture in postmenopausal Canadian women: a population-based prevalence study.

  2007cited by this paper
• The Prevalence of and the Clinical and Demographic Characteristics Associated With High-Intensity Proton Pump Inhibitor Use

  2007cited by this paper
• Long-term proton pump inhibitor therapy and risk of hip fracture.

  2006cited by this paper
• The importance of spectrum bias on bone density monitoring in clinical practice.

  2006cited by this paper
• Calcium absorption and achlorhydria.

  2006cited by this paper
• Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture

  2006cited by this paper
• Construction and validation of a population-based bone densitometry database.

  2005cited by this paper
• Hip fracture in women without osteoporosis.

  2005cited by this paper
• Health-related quality of life after osteoporotic fractures

  2004cited by this paper
• Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study.

  2004cited by this paper
• BMD at Multiple Sites and Risk of Fracture of Multiple Types: Long‐Term Results From the Study of Osteoporotic Fractures

  2003cited by this paper
• Osteopetrosis.

  2003cited by this paper
• AGA technical review on osteoporosis in gastrointestinal diseases.

  2003cited by this paper
• Use of Inhaled Corticosteroids and Risk of Fractures

  2001cited by this paper
• Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes.

  2001cited by this paper
• Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats.

  2001cited by this paper
• Use of Oral Corticosteroids and Risk of Fractures

  2000cited by this paper
• The Incidence of Fracture among Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study

  2000cited by this paper
• The Bioavailability of Dietary Calcium

  2000cited by this paper
• Establishing a population data-based policy unit.

  1999cited by this paper
• Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system.

  1999cited by this paper
• Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group.

  1998cited by this paper
• Physical Activity and Osteoporotic Fracture Risk in Older Women

  1998cited by this paper
• Mortality following fractures in older women. The study of osteoporotic fractures.

  1997cited by this paper
• Weight change and fractures in older women. Study of Osteoporotic Fractures Research Group.

  1997cited by this paper
• Weight Change and Fractures in Older Women

  1997cited by this paper
• Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III

  1997cited by this paper
• Mortality Following Fractures in Older Women: The Study of Osteoporotic Fractures

  1996cited by this paper
• Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.

  1995cited by this paper
• Calcium/phosphate/vitamin D homeostasis and bone mass in patients after gastrectomy, vagotomy, and cholecystectomy

  1995cited by this paper
• Growth of the parathyroid glands in omeprazole-treated chickens.

  1994cited by this paper
• Predicting femoral neck strength from bone mineral data. A structural approach.

  1990cited by this paper
• Calcium absorption and achlorhydria.

  1985cited by this paper
• An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium.

  1984cited by this paper
• Highlights of the conference

  1983cited by this paper
• The parathyroid glands in experimentally induced hypergastrinemia in the rat.

  1977cited by this paper

• Assessing the effect of DXA scanner drift on misclassification of bone density change: The Manitoba BMD registry.

  2025cites this paper
• Regular Proton-Pump Inhibitor Intake is Associated with Deterioration of Peripheral Bone Mineral Density, Microarchitecture, and Strength in Older Patients as Assessed by High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)

  2025cites this paper
• Proton pump inhibitor exposure, trabecular bone score, and BMD: a registry-based cohort study

  2025cites this paper
• Gastroesophageal reflux disease and osteoporosis: A bidirectional Mendelian randomization study

  2025influential citation
• Comparison of Vicious Effect of Oral Pantoprazole and Famotidine on New Bone Formation in Patients With Lumbar Spine Fusion Surgery: A Randomized Control Trial

  2024cites this paper
• Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density

  2024cites this paper
• The Effect of Smoking Cessation versus Current Smoking on Fracture Risk: The Manitoba BMD Registry.

  2024cites this paper
• The Aging Stomach: Clinical Implications of H. pylori Infection in Older Adults—Challenges and Strategies for Improved Management

  2024influential citation
• Bone mineral changes in young adult females on short-term proton pump inhibitor: A retrospective cohort study

  2024cites this paper
• Effects of Prolonged Proton-Pump Inhibitor Use on Renal Dysfunction and Bone Fragility

  2024cites this paper
• Proton pump inhibitors, bone and phosphocalcic metabolism.

  2024cites this paper
• Antacids in real clinical practice

  2023cites this paper
• Bone microstructure in proton pump inhibitor users.

  2023cites this paper
• Different effects of chronic omeprazole use on osteoporotic fractures rate in the elderly

  2023cites this paper
• Relevance of early management by proton-pump inhibitor in acute upper gastro-intestinal tract disorder: A scoping review.

  2023cites this paper
• The influence of proton pump inhibitors on tissue attachment around teeth and dental implants: A scoping review

  2022cites this paper
• Proton Pump Inhibitors and Bone Health: An Update Narrative Review

  2022cites this paper
• PPI‐Induced Changes in Plasma Metabolite Levels Influence Total Hip Bone Mineral Density in a UK Cohort

  2022cites this paper
• Changes in bone turnover markers in adolescents with gastroesophageal reflux disease treated with lansoprazole.

  2022cites this paper
• Proton pump inhibitors in allergy: benefits and risks.

  2022cites this paper
• Clinical Use of Lansoprazole and the Risk of Osteoporosis: A Nationwide Cohort Study

  2022cites this paper
• Proton pump inhibitors: Assessment of side effects and application in COVID-19 infection

  2022cites this paper
• Suppression of vacuolar-type ATPase and induction of endoplasmic reticulum stress by proton pump inhibitors

  2022cites this paper
• Long‐term proton pump inhibitor use and risk of osteoporosis and hip fractures: A nationwide population‐based and multicenter cohort study using a common data model

  2022cites this paper
• O AUMENTO DO RISCO DE OSTEOPOROSE ASSOCIADA AO USO CRÔNICO DOS INIBIDORES DA BOMBA DE PRÓTONS: UMA REVISÃO BIBLIOGRÁFICA INTEGRATIVA

  2022cites this paper
• Prolonged Use of Proton Pump Inhibitors, but Not Histamine-2 Receptor Antagonists, Is Associated With Lower Bone Mineral Density in Males Aged Over 70

  2021cites this paper
• Secondary Osteoporosis

  2021cites this paper
• Proton Pump Inhibitors in 2021: Pros, Cons, and Everything in Between

  2021cites this paper
• Acid-Suppressive Drugs and Risk of Fracture in Children and Young Adults: A Meta-Analysis of Observational Studies

  2021cites this paper
• Do patients with gastroesophageal reflux disease exhibit compromised bone quality prior to proton pump inhibitor therapy?

  2021cites this paper
• Long-term use of proton pump inhibitors adversely affects minerals and vitamin metabolism, bone turnover, bone mass, and bone strength

  2021cites this paper
• Proton Pompa İnhibitörlerinin Kırık Oluşumuna Etkisi ve Bakıma Yansıması

  2021cites this paper
• Statin Supply and Polydrug Use in Older Adults: A Focus on Drug Combinations that Reduce Bone Density

  2021cites this paper
• Toxicité des inhibiteurs de la pompe à protons

  2021cites this paper
• Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature

  2021cites this paper
• Proton-Pump Inhibitors: Do Children Break a Leg by Using Them?

  2021cites this paper
• Infecções hospitalares relacionadas ao uso de inibidores da bomba de prótons

  2020cites this paper
• Гастроэнтеропротекция при лечении эрозивно-язвенных поражений желудка и тонкой кишки

  2020cites this paper
• Associations between Proton Pump Inhibitor and Histamine-2 Receptor Antagonist and Bone Mineral Density among Kidney Transplant Recipients

  2020cites this paper
• Bone metabolism in inflammatory bowel diseases 1.

  2020cites this paper
• Effect of proton pump inhibitors on dental implants: A systematic review and meta-analysis

  2020cites this paper
• Proton Pump Inhibitor Controversies

  2020cites this paper
• Proton Pump Inhibitors: The Good, Bad, and Ugly.

  2020cites this paper
• Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease

  2020cites this paper
• Laryngopharyngeal and Gastroesophageal Reflux: A Comprehensive Guide to Diagnosis, Treatment, and Diet-Based Approaches

  2020cites this paper
• Biomarkers for Stool Analysis

  2020cites this paper
• Proton Pump Inhibitors Adversely Induce Selective Changes in the Bone Mineral Density Detected by Dual-Energy X-ray Absorptiometry in Postmenopausal Women

  2020cites this paper
• Male Osteoporosis: Gender Differences in Pathophysiology, Clinical Aspects, Diagnosis and Treatment

  2020cites this paper
• Foregut Surgery: Achalasia, Gastroesophageal Reflux Disease and Obesity

  2020cites this paper
• Potential proton pump inhibitor–related adverse effects

  2020cites this paper
• Protonenpumpeninhibitoren und Osteoporoserisiko

  2020cites this paper
• Association between proton pump inhibitor use and risk of fracture: A population-based case-control study

  2020cites this paper
• Esophageal injury associated with catheter ablation for atrial fibrillation: Determinants of risk and protective strategies

  2020cites this paper
• Drug-Induced Male Osteoporosis

  2020cites this paper
• Gastroprotection in the treatment of erosive and ulcerative lesions of the stomach and small intestine

  2020cites this paper
• Chapter 13: Heartburn and Dyspepsia

  2020cites this paper
• The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors.

  2020cites this paper
• Supplement With Calcium or Alendronate Suppresses Osteopenia Due to Long Term Rabeprazole Treatment in Female Mice: Influence on Bone TRAP and Osteopontin Levels

  2020cites this paper
• Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.

  2020cites this paper
• Enfermedad por reflujo gastroesofágico

  2019cites this paper
• A Study on the Status of Proton Pump Inhibitor Prescriptions Using Diagnosis Procedure Combination Data in Japan

  2019cites this paper
• Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome

  2019cites this paper
• The Safety of Long-term Daily Usage of a Proton Pump Inhibitor: A Literature Review

  2019cites this paper
• In search of the grail: A race for acid suppression

  2019cites this paper
• Proton pump inhibitors therapy and risk of bone diseases: An update meta‐analysis

  2019cites this paper
• Adverse Effects of Proton Pump Inhibitors—Evidence and Plausibility

  2019cites this paper
• Association of Vitamin D and Parathyroid Hormone With Barrett’s Esophagus

  2019cites this paper
• In search of the grail : A race for acid suppression

  2019cites this paper
• In search of the grail: A race for acid suppression.

  2019cites this paper
• Medical Treatment of GERD

  2019cites this paper
• The impact of proton pump inhibitors on bone regeneration and implant osseointegration

  2019cites this paper
• Early Acid Suppression Therapy Exposure and Fracture in Young Children

  2019cites this paper
• Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study

  2019cites this paper
• Gastroösophageale Refluxkrankheit

  2019cites this paper
• Proton pump inhibitors and fracture risk. The HUNT study, Norway

  2019cites this paper
• Diagnosis and treatment of gastroesophageal reflux disease : recommendations of the Asociación Mexicana

  2018cites this paper
• Proton pump inhibitors: Review of reported risks and controversies

  2018cites this paper
• Side Effects of Long‐Term Proton Pump Inhibitor Use: A Review

  2018cites this paper
• Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use

  2018cites this paper
• PPIs in Deutschland: zu oft, zu lange, zu viel?

  2018cites this paper
• Proton pump inhibitors’ use and risk of hip fracture: a systematic review and meta-analysis

  2018cites this paper
• Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?

  2018cites this paper
• Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis

  2018cites this paper
• Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis

  2018cites this paper
• Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.

  2018cites this paper
• Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study

  2018cites this paper
• Evidence of Drug–Nutrient Interactions with Chronic Use of Commonly Prescribed Medications: An Update

  2018cites this paper
• Do recent reports about the adverse effects of proton pump inhibitors change providers' prescription practice?

  2018cites this paper
• Quantifying Candidacy for Deprescribing of Proton Pump Inhibitors among Long-Term Care Residents.

  2018cites this paper
• Proton Pump Inhibitor Use, H2-Receptor Antagonist Use, and Risk of Incident Clinical Vertebral Fracture in Women

  2018cites this paper
• Do acid suppressive drugs (pantoprazole and ranitidine) attenuate the protective effect of alendronate in estrogen-deficient osteoporotic rats?

  2017cites this paper
• Acute Effects Of Oral Calcium Carbonate With And Without The Addition Of Omeprazole And Fiber Enriched Milk On Serum Calcium Concentrations In Postmenopausal Women

  2017cites this paper
• Proton-pump inhibitors: understanding the complications and risks

  2017cites this paper
• Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System

  2017cites this paper
• Bone Mineral Density 1 The Effect of Omeprazole on Bone Mineral Density in Wistar Rats

  2017cites this paper
• Osteoporosis in Patients with Peripheral Neuropathies

  2017cites this paper
• A Proton Pump Inhibitor in the Reformulation Setting: Bioequivalence and Potential Implications for Long‐Term Safety

  2017cites this paper
• Protonenpumpenhemmer – Nebenwirkungen und Komplikationen der langfristigen Protonenpumpenhemmereinnahme

  2017cites this paper
• Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence

  2017cites this paper
• Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure

  2017cites this paper